Leukemia Research
Volume 27, Issue 1 , Pages 73-78 , January 2003

Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma

Received 1 February 2001 ,Accepted 1 April 2002.

References 

  1. Epstein J, Barlogie B, Katzmann J, Alexanian R. Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B-cell involvement. Blood. 1988;71:861
  2. Berenson J, Wong R, Kim K, Brown N, Lichtenstein A. Evidence for peripheral blood B lymphocyte but not T lymphocyte involvement in multiple myeloma. Blood. 1987;70:1550
  3. Klein G. Comparative action of myc and bcl-2 in B-cell malignancy. Cancer Cells. 1991;3:141
  4. Brown RD, Pope B, Luo XF, Gibson J, Joshua D. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk. Lymphoma. 1994;16:147
  5. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250
  6. Palumbo AP, Pileri A, Dianzani U, Massaia M, Boccadoro M, Calabretta B. Altered expression of growth-regulated protooncogenes in human malignant plasma cells. Cancer Res. 1989;49:4701
  7. Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C, et al.  Mutations of the p53 gene in human myeloma cell lines. Oncogene. 1992;7:1015; [published erratum appears in Oncogene 1993;8(4):1107]
  8. Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, et al.  p53 and ras gene mutations in multiple myeloma. Oncogene. 1992;7:2539
  9. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81:128
  10. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523
  11. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912
  12. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, et al.  Gebhardt, p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 1990;10:5772
  13. Chen YM, Chen PL, Arnaiz N, Goodrich D, Lee WH. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Oncogene. 1991;6:1799
  14. Johnson P, Gray D, Mowat M, Benchimol S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol. Cell. Biol. 1991;11:1
  15. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene. 1991;6:1791
  16. Shaulsky G, Goldfinger N, Rotter V. Alterations in tumor development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res. 1991;51:5232
  17. Mukhopadhyay T, Roth JA. A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Res. 1993;53:4362
  18. Bayever E, Haines KM, Iversen PL, Ruddon RW, Pirruccello SJ, Mountjoy CP, et al.  Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk. Lymphoma. 1994;12:223
  19. Srivastava CH, Samulski RJ, Lu L, Larsen SH, Srivastava A. Construction of a recombinant human parvovirus B19: adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus. Proc. Natl. Acad. Sci. U.S.A. 1989;86:8078
  20. Epstein J, Hoover R, Kornbluth J, Barlogie B. Biological aspects of multiple myeloma. Baillieres Clin. Haematol. 1995;8:721
  21. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453
  22. Yasuga Y, Hirosawa S, Yamamoto K, Tomiyama J, Nagata K, Aokia N. N-ras and p53 gene mutations are very rare events in multiple myeloma. Int. J. Hematol. 1995;62:91
  23. Raff MC. Social controls on cell survival and cell death. Nature. 1992;356:397
  24. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc. Natl. Acad. Sci. U.S.A. 1991;88:8982
  25. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54:2095
  26. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 1993;8:3427
  27. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131
  28. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, et al.  Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 1994;54:3253
  29. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81:151
  30. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, et al.  Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063

PII: S0145-2126(02)00064-4

Leukemia Research
Volume 27, Issue 1 , Pages 73-78 , January 2003

Article Tools

* Image Usage & Resolution